{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:51Z","timestamp":1789419831221,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    This meta\u2010analysis evaluated the risk of malignancies and major adverse cardiovascular events (MACE) associated with the use of JAK inhibitors in patients with RA through a comprehensive meta\u2010analysis of available clinical trials. A systematic search was conducted in PubMed, EMBASE, and Web of Science from inception to February 7, 2025, to identify relevant clinical trials. Data on malignancies and MACE incidence were extracted, and pooled risk ratios (RR) were calculated using a random\u2010effects model. A total of 18 studies (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009111,260) met the inclusion criteria. JAK inhibitors were associated with a significantly increased risk of malignancies excluding NMSC (RR\u2009=\u20091.30, 95%CI: 1.05, 1.60;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.016), NMSC (RR\u2009=\u20091.54, 95%CI: 1.23, 1.93;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01), overall malignancies (RR\u2009=\u20091.53, 95%CI: 1.18, 2.00;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002), lung cancer (RR\u2009=\u20091.52, 95%CI: 1.11, 2.08;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.009), lymphoma (RR\u2009=\u20093.69, 95%CI: 1.19, 11.42;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.024), non\u2010small cell lung cancer (RR\u2009=\u20091.70, 95%CI: 1.01, 2.86;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.047), cutaneous squamous cell carcinoma (RR\u2009=\u20092.30, 95%CI: 1.44, 3.65;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01), and thyroid cancer (RR\u2009=\u20097.51, 95%CI: 1.39, 40.74;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.019). In contrast, JAK inhibitors did not significantly alter the risk of MACE (RR\u2009=\u20090.75, 95%CI: 0.38, 1.45;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.390), venous thromboembolism (VTE) (RR\u2009=\u20091.52, 95%CI: 0.90, 2.56;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.117), or deep vein thrombosis (DVT) (RR\u2009=\u20091.77, 95%CI: 0.84, 3.34;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.079). Trial sequential analysis (TSA) confirmed data adequacy, and meta\u2010regression indicated that sample size, treatment duration, and patient age did not influence outcomes. JAK inhibitors are associated with an elevated risk of malignancies but do not significantly affect MACE, VTE, or DVT risk in RA patients. Further large\u2010scale post\u2010marketing surveillance is warranted to refine the safety profile of JAK inhibitors in RA management.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70146","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:07:51Z","timestamp":1766405271000},"page":"598-607","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of Malignancies and Major Adverse Cardiovascular Events Related to\n                    <scp>JAK<\/scp>\n                    Inhibitors in Rheumatoid Arthritis: A Meta\u2010Analysis"],"prefix":"10.1002","volume":"119","author":[{"given":"Hongmei","family":"Duan","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology First Affiliated Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Shengjing Hospital of China Medical University  Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binglun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics ShengJing Hospital of China Medical University  Shenyang City Liaoning Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hefan","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Shengjing Hospital of China Medical University  Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Orthopedics Shengjing Hospital of China Medical University  Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Orthopedics Shengjing Hospital of China Medical University  Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics First affiliation Hospital of China Medical University  Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152586"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.102032"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111880"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.07.027"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.006"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01062-9"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000972"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05911-4"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa895"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2023045"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac084"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1859675"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac083"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222405"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab030"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001621"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224482"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39953"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42250"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002106"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39953"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2741"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6473"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0320-3"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003912"},{"key":"e_1_2_11_42_1","first-page":"4064","article-title":"The risk of venous thromboembolic events in patients with RA aged \u2265\u200950\u2009years with \u2265\u20091 cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of Tofacitinib vs TNF inhibitors: abstract number: 1941","volume":"73","author":"Szekanecz Z.","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"e_1_2_11_43_1","unstructured":"Pfizer: Pfizer announces modification to ongoing tofacitinib FDA post\u2010marketing requirement study in patients with rheumatoid arthritis(2019)."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224049"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07360-9"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:10:15Z","timestamp":1771312215000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cpt.70146"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70146","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"2025-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}